CAR T-cell therapy with daratumumab for relapsed multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new treatment that combines two types of therapy: CAR T-cell therapy (which uses your own immune cells to fight the cancer) and daratumumab (a drug that targets a protein on myeloma cells). The goal is to see if this combination can help people with relapsed or refractory multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 79 years old.
- You must have already tried at least 3 different treatments for multiple myeloma (including a proteasome inhibitor, an immunomodulator, and a CD38-targeted drug).
- Your cancer must be measurable, meaning lab tests show active disease (like high M-protein in blood or urine).
- You should be relatively active and able to care for yourself (a Karnofsky score of 70 or higher).
- Your liver, kidneys, heart, and lungs must be working well enough to handle the treatment.
- You must agree to use reliable birth control during the study and for a period after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and destroy myeloma cells that have a protein called BCMA. It is for people whose multiple myeloma has come back or hasn't responded to other treatments.
This Phase 1 study tests an experimental CAR T-cell treatment that targets BCMA in people with relapsed or refractory multiple myeloma. It may help shrink the cancer after it has not responded to several prior therapies.
This study tests a new type of immune cell therapy (CAR T-cells) for people with advanced multiple myeloma that has relapsed or not responded to standard treatments. The goal is to see if this therapy is safe and to understand its potential benefits.
This trial tests a new treatment called CAR-T cell therapy for people with multiple myeloma that has come back or not responded to other treatments. The treatment uses your own immune cells, modified in a lab to attack the cancer, and may be an option after a stem cell transplant has not worked.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Hear when a new Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.